Skip to main content
Have a personal or library account? Click to login
Abnormalities in soluble CD147 / MMPs / TIMPs axis in Ankylosing Spondylitis patients with and without a history of Acute Anterior Uveitis / Anomalii ale axei CD147 solubil / MMPs / TIMPs la pacienții cu spondilită anchilozantă cu sau fără uveită acută anterioară Cover

Abnormalities in soluble CD147 / MMPs / TIMPs axis in Ankylosing Spondylitis patients with and without a history of Acute Anterior Uveitis / Anomalii ale axei CD147 solubil / MMPs / TIMPs la pacienții cu spondilită anchilozantă cu sau fără uveită acută anterioară

Revista Romana de Medicina de Laborator
Volume 22 (2014): Issue 4 (December 2014)
By: ,  ,  ,  ,   and    
Open Access
|Dec 2014
References

References

  1. 1. Slobodin G, Rosner I, Rimar D, Boulman N, Rozenbaum M, Odeh M. Ankylosing spondylitis: field in progress. Isr Med Assoc J. 2012;14(12):763-7.
    Search in Google Scholar
  2. 2. Thomas GP, Brown MA. Genetics and genomics of ankylosing spondylitis. Immunol Rev. 2010;233(1):162-80. DOI: 10.1111/j.0105-2896.2009.00852.x
    Open DOISearch in Google Scholar
  3. 3. Snelgrove T, Lim S, Greenwood C, Peddle L, Hamilton S, Inman R, et al. Association of toll-like receptor 4 variants and ankylosing spondylitis: a case-control study. J Rheumatol. 2007;34(2):368-70.
    Search in Google Scholar
  4. 4. De Vlam K. Soluble and tissue biomarkers in ankylosing spondylitis. Best Pract Res Clin Rheumatol. 2010;24(5):671-82. DOI: 10.1016/j.berh.2010.05.009
    Open DOISearch in Google Scholar
  5. 5. Wang QH, Zhang SZ, Xue J, Wu HX. Serum metalloproteinase-3 levels in assessing efficacy of Etanercept in patients with ankylosing spondylitis. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2010;39(4):409-14 (abstract).
    Search in Google Scholar
  6. 6. Maksymowych WP, Landewé R, Conner-Spady B, Dougados M, Mielants H, van der Tempel H, Poole AR, Wang N, van der Heijde D. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis.
    Search in Google Scholar
  7. Arthritis Rheum. 2007;56(6):1846-53 DOI: 10.1002/ art.22589
    Search in Google Scholar
  8. 7. Gouveia EB, Elmann D, Morales MS. Ankylosing spondylitis and uveitis: overview. Rev Bras Reumatol. 2012;52(5):742-56.
    Search in Google Scholar
  9. 8. El Maghraoui A. Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur J Intern Med. 2011;22(6):554-60. DOI: 10.1016/j.ejim.2011.06.006
    Open DOISearch in Google Scholar
  10. 9. Robertson LP, Davis MJ. A longitudinal study of disease activity and functional status in a hospital cohort of patients with ankylosing spondylitis. Rheumatology (Oxford). 2004;43(12):1565-8. DOI: 10.1093/rheumatology/ keh386
    Search in Google Scholar
  11. 10. Chang JH, McCluskey PJ, Wakefield D. 2009. Acute Anterior Uveitis and HLA-B27: What’s New? in Uveitis and Immunological Disorders Progress III, U Pleyer, JV Forrester eds. Springer-Verlag, Berlin Heidelberg. p. 9-18. DOI: 10.1007/978-3-540-69459-5_2
    Open DOISearch in Google Scholar
  12. 11. Li H, Yoneda M, Takeyama M, Sugita I, Tsunekawa H, Yamada H, et al. Effect of infliximab on tumor necrosis factor-alpha-induced alterations in retinal microvascular endothelial cells and retinal pigment epithelial cells. J Ocul Pharmacol Ther. 2010;26(6):549-56. DOI: 10.1089/jop.2010.0079
    Open DOISearch in Google Scholar
  13. 12. Di Girolamo N, Verma MJ, McCluskey PJ, Lloyd A, Wakefield D. Increased matrix metalloproteinases in the aqueous humor of patients and experimental animals with uveitis. Curr Eye Res. 1996;15(10):1060-8.
    Open DOISearch in Google Scholar
  14. DOI: 10.3109/02713689609017656
    Open DOISearch in Google Scholar
  15. 13. Cuello C, Wakefield D, Di Girolamo N. Neutrophil accumulation correlates with type IV collagenase/gelatinase activity in endotoxin induced uveitis. Br J Ophtalmol. 2002;86(3):290-5. DOI: 10.1136/bjo.86.3.290
    Open DOISearch in Google Scholar
  16. 14. Yamada H, Yoneda M, Inaguma S, Watanabe D, Banno S, Yoshikawa K, et al. Infliximab counteracts tumor necrosis factor-α-enhanced induction of matrix metalloproteinases that degrade claudin and occludin in non-pigmented ciliary epithelium. Biochem Pharmacol. 2013;85(12):1770-82. DOI: 10.1016/j.bcp.2013.04.006
    Open DOISearch in Google Scholar
  17. 15. Martin TM, Bye L, Modi N, Stanford MR, Vaughan R, Smith JR, et al. Genotype analysis of polymorphisms in autoimmune susceptibility genes, CTLA-4 and PTPN22, in an acute anterior uveitis cohort. Mol Vis. 2009;15:208-12.
    Search in Google Scholar
  18. 16. Fossum S, Mallett S, Barclay AN. The MRC OX-47 antigen is a member of the immunoglobulin superfamily with an unusual transmembrane sequence. Eur J Immunol. 1991;21(3):671-9. DOI: 10.1002/eji.1830210320
    Open DOISearch in Google Scholar
  19. 17. Koch C, Staffler G, Hüttinger R, Hilgert I, Prager E, Cerný J, et al. T cell activation-associated epitopes of CD147 in regulation of the T cell response, and their definition by antibody affinity and antigen density.
    Search in Google Scholar
  20. Int Immunol. 1999;11(5):777-86. DOI: 10.1093/intimm/
    Search in Google Scholar
  21. 11.5.777
    Search in Google Scholar
  22. 18. Määttä M, Tervahartiala T, Kaarniranta K, Tang Y, Yan L, Tuukkanen J, et al. Immunolocalization of EMMPRIN (CD147) in the human eye and detection of soluble form of EMMPRIN in ocular fluids. Curr Eye Res. 2006;31(11):917-24. DOI: 10.1080/02713680600932290
    Open DOISearch in Google Scholar
  23. 19. Biswas C. Tumor cell stimulation of collagenase production by fibroblasts. Biochem Biophys Res Commun. 1982;109(3):1026-34. DOI: 10.1016/0006-291X(82)92042-3
    Open DOISearch in Google Scholar
  24. 20. Philp NJ, Ochrietor JD, Rudoy C, Muramatsu T, Linser PJ. Loss of MCT1, MCT3, and MCT4 expression in the retinal pigment epithelium and neural retina of the 5A11/basigin-null mouse. Invest Ophthalmol Vis Sci. 2003;44(3):1305-11. DOI: 10.1167/iovs.02-0552
    Open DOISearch in Google Scholar
  25. 21. Gabison EE, Mourah S, Steinfels E, Yan L, Hoang-Xuan T, Watsky MA, et al. Differential expression of extracellular matrix metalloproteinase inducer (CD147) in normal and ulcerated corneas: role in epithelio-stromal interactions and matrix metalloproteinase induction.
    Search in Google Scholar
  26. Am J Pathol. 2005;166(1):209-19. DOI: 10.1016/ S0002-9440(10)62245-6
    Search in Google Scholar
  27. 22. Iacono KT, Brown AL, Greene MI, Saouaf SJ. CD147 immunoglobulin superfamily receptor function and role in pathology. Exp Mol Pathol. 2007;83(3):283-95.
    Open DOISearch in Google Scholar
  28. DOI: 10.1016/j.yexmp.2007.08.014
    Open DOISearch in Google Scholar
  29. 23. Taylor PM, Woodfield RJ, Hodgkin MN, Pettitt TR, Martin A, Kerr DJ, et al. Breast cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A(2) and 5-lipoxygenase catalyzed pathway.
    Search in Google Scholar
  30. Oncogene. 2002;21(37):5765-72. DOI: 10.1038/ sj.onc.1205702
    Open DOISearch in Google Scholar
  31. 24. Sidhu SS, Mengistab AT, Tauscher AN, LaVail J, Basbaum C. The microvesicle as a vehicle for EMMPRIN in tumor-stromal interactions. Oncogene. 2004;23(4):956-63. DOI: 10.1038/sj.onc.1207070
    Open DOISearch in Google Scholar
  32. 25. Egawa N, Koshikawa N, Tomari T, Nabeshima K, Isobe T, Seiki M. Membrane type 1 matrix metalloproteinase (MT1-MMP/MMP-14) cleaves and releases a 22-kDa extracellular matrix metalloproteinase inducer (EMMPRIN) fragment from tumor cells. J Biol Chem. 2006;281(49):37576-85. DOI: 10.1074/jbc.
    Open DOISearch in Google Scholar
  33. M606993200
    Search in Google Scholar
  34. 26. Onodera J, Onodera S, Kondo E, Betsuyaku T, Yasuda K. A soluble factor (EMMPRIN) in exudate influences knee motion after total arthroplasty. Knee Surg Sports Traumatol Arthrosc. 2009;17(3):298-304. DOI: 10.1007/s00167-008-0688-6
    Open DOISearch in Google Scholar
  35. 27. Yanaba K, Asano Y, Tada Y, Sugaya M, Kadono T, Hamaguchi Y, et al. Increased serum soluble CD147 levels in patients with systemic sclerosis: association with scleroderma renal crisis. Clin Rheumatol. 2012;31(5):835-9. DOI: 10.1007/s10067-012-1949-9
    Open DOISearch in Google Scholar
  36. 28. Wang M, Huang ZX, Pan YF, Zhang FC, Zheng BR, Deng WM, et al. Expressions of CD147 in peripheral monocytes and T lymphocytes of patients with ankylosing spondylitis. Zhonghua Yi Xue Za Zhi. 2010;90(41):2902-6 (abstract).
    Search in Google Scholar
  37. 29. Dhir V, Srivastava R, Aggarwal A. Circulating Levels of Soluble Receptor Activator of NF- κ B Ligand and Matrix Metalloproteinase 3 (and Their Antagonists) in Asian Indian Patients with Ankylosing Spondylitis.
    Search in Google Scholar
  38. Int J Rheumatol. 2013;2013:814350. DOI: 10.1155/2013/814350
    Open DOISearch in Google Scholar
  39. 30. Veidal SS, Larsen DV, Chen X, Sun S, Zheng Q, Bay-Jensen AC, et al. MMP mediated type V collagen degradation (C5M) is elevated in ankylosing spondylitis.
    Search in Google Scholar
  40. Clin Biochem. 2012;45(7-8):541-6 DOI: 10.1016/j. clinbiochem.2012.02.007
    Search in Google Scholar
  41. 31. Mattey DL, Packham JC, Nixon NB, Coates L, Creamer P, Hailwood S, et al. Association of cytokine and matrix metalloproteinase profiles with disease activity and function in ankylosing spondylitis. Arthritis Res Ther. 2012;14(3):R127 DOI: 10.1186/ar3857
    Open DOISearch in Google Scholar
  42. 32. Moll JM, Wright V. New York clinical criteria for ankylosing spondylitis. A statistical evaluation. Ann Rheum Dis. 1973;32(4):354-63. DOI: 10.1136/ard.32.4.354
    Open DOISearch in Google Scholar
  43. 33. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis.
    Search in Google Scholar
  44. A proposal for modification of the New York criteria.
    Search in Google Scholar
  45. Arthritis Rheum. 1984;27(4):361-8. DOI: 10.1002/ art.1780270401
    Open DOISearch in Google Scholar
  46. 34. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286-91.
    Search in Google Scholar
  47. 35. Lukas C, Landewé R, Sieper J, Dougados M, Davis J, Braun J, et al. Assessment of SpondyloArthritis international Society. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(1):18-24.
    Open DOISearch in Google Scholar
  48. DOI: 10.1136/ard.2008.094870
    Open DOISearch in Google Scholar
  49. 36. Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21(12):2281-5.
    Search in Google Scholar
  50. 37. Matache C, Stefanescu M, Dragomir C, Tanaseanu S, Onu A, Ofiteru A, et al. Matrix metalloproteinase-9 and its natural inhibitor TIMP-1 expressed or secreted by peripheral blood mononuclear cells from patients with systemic lupus erythematosus. J Autoimmun. 2003; 20(4): 323-31. DOI: 10.1016/S0896-8411(03)00037-4
    Open DOISearch in Google Scholar
  51. 38. Chen CH, Lin KC, Chen HA, Liao HT, Liang TH, Wang HP, et al. Association of acute anterior uveitis with disease activity, functional ability and physical mobility in patients with ankylosing spondylitis: a cross-sectional study of Chinese patients in Taiwan. Clin Rheumatol. 2007;26(6):953-7. DOI: 10.1007/s10067-006-0403-2
    Open DOISearch in Google Scholar
  52. 39. Berg IJ, Semb AG, van der Heijde D, Kvien TK, Hisdal J, Olsen IC, et al. Uveitis is associated to hypertension and atherosclerosis in patients with ankylosing spondylitis: a cross-sectional study. Semin Arthritis Rheum.
    Search in Google Scholar
  53. 2014. pii: S0049-0172(14)00111-5. doi: 10.1016/j. semarthrit.2014.05.017. DOI: 10.1016/j.semarthrit.
    Search in Google Scholar
  54. 2014.05.017
    Search in Google Scholar
  55. 40. Cordiali-Fei P, Trento E, D’Agosto G, Bordignon V, Mussi A, Ardigó M, et al. Effective therapy with anti- TNF-alpha in patients with psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in the sera and skin lesions.
    Search in Google Scholar
  56. Ann N Y Acad Sci. 2007;1110:578-89. DOI: 10.1196/ annals.1423.062
    Search in Google Scholar
  57. 41. Chen CH, Lin KC, Yu DT, Yang C, Huang F, Chen HA, et al. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology (Oxford). 2006;45(4):414-20. DOI: 10.1093/rheumatology/kei208
    Open DOISearch in Google Scholar
  58. 42. Yurchenko V, Constant S, Eisenmesser E, Bukrinsky M. Cyclophilin-CD147 interactions: a new target for anti-inflammatory therapeutics. Clin Exp Immunol. 2010;160(3):305-17. DOI: 10.1111/j.1365-2249.2010.04115.x
    Open DOISearch in Google Scholar
  59. 43. Pistol G, Matache C, Calugaru A, Stavaru C, Tanaseanu S, Ionescu R, et al. Roles of CD147 on T lymphocytes activation and MMP-9 secretion in systemic lupus erythematosus.
    Search in Google Scholar
  60. J Cell Mol Med. 2007;11(2):339-48. DOI: 10.1111/j.1582-4934.2007.00022.x
    Open DOISearch in Google Scholar
  61. 44. Han YP, Tuan TL, Wu H, Hughes M, Garner WL.
    Search in Google Scholar
  62. TNF-alpha stimulates activation of pro-MMP2 in human skin through NF-(kappa)B mediated induction of MT1-MMP. J Cell Sci. 2001;114(Pt 1):131-139.
    Open DOISearch in Google Scholar
  63. 45. Bellayr IH, Mu X, Li Y. Biochemical insights into the role of matrix metalloproteinases in regeneration: challenges and recent developments. Future Med Chem. 2009;1(6):1095-111. DOI: 10.4155/fmc.09.83
    Open DOISearch in Google Scholar
  64. 46. Kaneider NC, Mosheimer B, Günther A, Feistritzer C, Wiedermann CJ. Enhancement of fibrinogen-triggered pro-coagulant activation of monocytes in vitro by matrix metalloproteinase-9. Thromb J. 2010;8(1):2-7.
    Open DOISearch in Google Scholar
  65. DOI: 10.1186/1477-9560-8-2
    Open DOISearch in Google Scholar
  66. 47. Tarhini AA, Lin Y, Yeku O, LaFramboise WA, Ashraf M, Sander C, et al. A four-marker signature of TNFRII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma. J Transl Med. 2014,12:19. DOI: 10.1186/1479-5876-12-19
    Open DOISearch in Google Scholar
  67. 48. Gehlen M, Regis KC, Skare TL. Demographic, clinical, laboratory and treatment characteristics of spondyloarthritis patients with and without acute anterior uveitis.
    Search in Google Scholar
  68. Sao Paolo Med J. 2012;130(3):141-4. DOI: 10.1590/ S1516-31802012000300002
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.2478/rrlm-2014-0039 | Journal eISSN: 2284-5623 | Journal ISSN: 1841-6624 (formerly 2284-5623)
Journal RSS Feed
Language: English, Romanian
Page range: 479 - 496
Submitted on: Jun 12, 2014
Accepted on: Nov 1, 2014
Published on: Dec 30, 2014
Published by: Romanian Association of Laboratory Medicine
In partnership with: Paradigm Publishing Services
Keywords:
Ankylosing Spondylitis,
Acute Anterior Uveitis,
soluble CD147,
MMPs,
TIMPs
Related subjects:
Life sciences,
Molecular biology

© 2014 Traian Costin Mitulescu, Liliana Mary Voinea, Denisa Predeteanu, Leontina Mirela Banica, Crina Stavaru, Cristiana Matache, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 22 (2014): Issue 4 (December 2014)
Previous article
Next article